J. Schulz

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

C. Fuchs, J. Marshall, V. Ganju, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

T. Szatrowski, T. Cartwright, J. Cox, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I S tudy o f O ral C apecitabine i n P atients W ith Advanced o r M etastatic P ancreatic C ancer

T. Szatrowski, T. Cartwright, J. Cox, 2002 .

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11

F. Kabbinavar, J. Hamm, B. Nelson, 2004 .

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

R. James, S. Clarke, J. Zalcberg, 2002, European journal of cancer.

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.

J. Forster, L. Schwartzberg, P. Wissel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J. Hecht, F. Kabbinavar, J. Hamm, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer

P. LoRusso, P. Schein, L. Baker, 2004, Cancer Chemotherapy and Pharmacology.

Randomized phase III study of 3 irinotecan regimens in 1st-line metastatic colorectal cancer (CRC): safety/tolerability of irinotecan + oral capecitabine with or without celecoxib (BICC)

C. Fuchs, J. Marshall, V. Ganju, 2005 .